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Abstract
Background: Urinary tract infection (UTI) is a leading cause of hospital admissions and is diagnosed based on
urinary symptoms and microbiological cultures. Due to lags in the availability of culture results of up to 72 h, and
the limitations of routine diagnostics, many patients with suspected UTI are started on antibiotic treatment
unnecessarily. Predictive models based on routinely collected clinical information may help clinicians to rule out a
diagnosis of bacterial UTI in low-risk patients shortly after hospital admission, providing additional evidence to
guide antibiotic treatment decisions.
Methods: Using electronic hospital records from Queen Elizabeth Hospital Birmingham (QEHB) collected between
2011 and 2017, we aim to develop a series of models that estimate the probability of bacterial UTI at presentation
in the emergency department (ED) among individuals with suspected UTI syndromes. Predictions will be made
during ED attendance and at different time points after hospital admission to assess whether predictive
performance may be improved over time as more information becomes available about patient status. All models
will be externally validated for expected future performance using QEHB data from 2018/2019.
Discussion: Risk prediction models using electronic health records offer a new approach to improve antibiotic
prescribing decisions, integrating clinical and demographic data with test results to stratify patients according to
their probability of bacterial infection. Used in conjunction with expert opinion, they may help clinicians to identify
patients that benefit the most from early antibiotic cessation.
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Background
Urinary tract infection (UTI) is a leading cause of hos-
pital admissions, accounting for 16% of all avoidable
emergency admissions [1]. UTI presents with a clinical
spectrum that ranges from urosepsis and pyelonephritis
to mild urinary symptoms, each of which merits differ-
ent durations of antibiotic treatment or potentially no
antibiotics at all [2, 3]. The diagnosis of UTI syndromes
is based on a combination of symptoms and microbio-
logical culture of urine (bacteriuria) and/or blood (bac-
teraemia) [4]. Obtaining microbiological results
introduces a bottleneck for evidence-based diagnosis,
since cultures often take 48–72 h to grow. In the mean-
time, patients are often treated with antibiotics. Previous
studies have found that up to 50% of such antibiotic use
is unnecessary [5–7]. A wide range of additional infor-
mation is collected as part of routine hospital care,
which may provide an opportunity to reduce the diag-
nostic uncertainty introduced by the delay in culture re-
sults. Stored within electronic health records (EHR),
these auxiliary data may help to create risk prediction
models that can be used to predict the likely culture re-
sult and identify patients who are highly unlikely to have
bacterial UTI.
We are aware of very few studies that have looked into
using routine health data to predict bacteriuria in emer-
gency department (ED) settings [8, 9]. In a recent study,
Taylor et al. predicted bacterial growth in urine sampled
from more than 80,000 patients with potential UTI
symptoms in four US EDs [8]. Their best performing
model achieved an area under the receiver operating
characteristic curve (AUROC) of 0.90, with a sensitivity
of 61.7% and a specificity of 94.9%. However, there are
several reasons why it is difficult to apply this model in
an NHS hospital including inclusion of urinalysis results
that are not regularly performed in the UK, a relatively
broad definition of the population at risk and the exclu-
sion of microbiological culture of blood. In the only
other study that we are aware of that attempted to pre-
dict bacteriuria in the ED, Wigton et al. achieved a lower
AUROC of 0.78 on a sample of 506 patients [9]. Several
further studies were performed in primary care settings
[10–14] but their generalisability to a generally sicker
ED population is questionable.
In this study, we will expand on previously published
work [8, 9] and develop a model which aims to judge
the probability of bacterial UTI in UK patients who
present with suspected UTI in the ED. The models will
be developed and tested using data on individuals pre-
senting in the ED at Queen Elizabeth Hospital Birming-
ham (QEHB). QEHB has EHR which are ideally suited
for this purpose, containing high-quality and detailed in-
formation on diagnoses, outcomes, investigations, vital
signs, drug treatments and diagnostic coding dating back
to 2011 [15]. Using these hospital records, our model aims
to predict the probability that urinary pathogens will grow
in urine and/or blood cultures collected during ED attend-
ance. For admitted patients, additional predictions will be
made at specific intervals throughout the first three days
of their hospital stay to investigate whether additional in-
formation gathered during their inpatient stay, but before
availability of culture results, allows to predict culture
growth with increased certainty. Finally, we will explore
differences in model performance and clinical progression
for important subpopulations including the elderly and
patients with a recorded alternative infective syndrome
(e.g. pneumonia) at arrival or discharge, which do not re-
quire antibiotics for UTI but may need them for the treat-
ment of the other infection.
Aims and objectives
Aim
To use EHR data from a large UK teaching hospital to
predict patients’ probability of bacterial UTI at arrival
among individuals with suspected UTI in the ED.
Objectives
a) To develop models that predict bacterial growth in
urine and/or blood samples collected during ED
attendance based on clinical information recorded
in the patient’s medical history and in the ED
b) To assess the change in predictive performance at
pre-defined times after admission (0, 12, 24, 36, 48,
60 and 72 h) to determine whether additional in-
patient data collected up to 72 h after admission to
hospital leads to increased predictive certainty
c) To compare the predictive performance of each
model in different subpopulations, considering sex,
age, clinical syndrome (lower UTI, pyelonephritis,
urosepsis), final diagnoses (UTI, other infection,
non-infective diagnosis) and risk of complications
(death, admission to intensive care, length of stay)
d) To evaluate the expected performance of our




QEHB is part of University Hospitals Birmingham NHS
Foundation Trust, one of the largest teaching hospitals
in England. The trust serves a population of more than
2.2 million patients per year, a large proportion of whom
are seen at QEHB [16]. Detailed information on all pa-
tients admitted to QEHB is recorded within its elec-
tronic patient management system, including clinical
diagnoses, observations, assessments and laboratory re-
sults [15]. Unlike many other trusts in England, QEHB
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has also recorded drug prescriptions electronically for
more than 10 years, making it an invaluable resource for
research linked to antibiotic prescribing.
Development dataset
To develop the predictive models, we will use data from
all eligible patients who attended the ED at QEHB be-
tween 1 November 2011 and 31 December 2017 (elec-
tronic recording of ED diagnosis at QEHB started after a
system change at the end of October 2011).
Validation dataset
We will use data collected at QEHB between 1 January
2018 and 31 March 2019 to externally validate the
model. Patients who were included in the development
dataset due to an earlier attendance will be excluded
from the validation dataset. We will undertake external
validation of our models in an independent dataset from
University College London Hospitals NHS Foundation
Trust.
Participants
Inclusion and exclusion criteria
All patients who attended the ED at QEHB within the
study period and who had a urine sample submitted for
microbiological testing within 24 h of arrival are eligible
for inclusion in the study. A window of 24 h was chosen
to account for discrepancies between when the sample
was collected and when the urine sample was recorded
in the laboratory system (particularly overnight). Patients
enter the study at registration in the ED and exit the
study on the earliest of the following dates: date of dis-
charge, date of death, date of transfer to a different hos-
pital or date of urine culture results.
Individuals aged < 18 years, pregnant women, patients
who were not admitted via the ED and patients whose
urine sample was submitted for culture but was not cul-
tured due to standard laboratory protocols at QEHB (see
the “Outcome” section for details) will be excluded from
the analysis.
Outcome
The principal outcome of interest is microbiological
growth (≥ 104 colony-forming units/mL). Only urine
samples that were eventually cultured will be included in
the analysis. Microbiological cultures at QEHB are per-
formed in accordance with standard laboratory proce-
dures (UK Standards for Microbiology Investigations:
SMI B41, Investigation of Urine; SMI B37, investigation
of blood cultures (for organisms other than Mycobacter-
ium species) [17]. The decision whether to culture a
urine sample depends on cell count results performed in
the laboratory. Only urines with white blood cell counts
and bacteria counts above a threshold value were
cultured. At the start of the study, the threshold value
for proceeding to culture was white cell counts > 40/μL
or bacteria counts > 4000/μL. This was adjusted to white
cell counts > 80/μL or bacteria counts > 8000/μL follow-
ing the introduction of a revised standard operating pro-
cedure in the microbiology laboratory in October 2015.
Performing cell counts is not possible for urine samples
less than 4 mL or for samples too viscous to pass
through the instrument. Samples for which cell counts
could not be performed are always cultured and in-
cluded in the analysis. Following the standard procedure
at QEHB, (heavy) mixed growth in the urine sample will
be considered as contamination, except where E. Coli
was present. In addition, samples will be classified as
positive if there are < 104 colony-forming units/mL but
the same urinary pathogen is identified from a blood
culture, implying urosepsis.
Predictors
We will consider a wide range of candidate predictors
relating to characteristics of the urine sample, a patient’s
clinical presentation at the start of and throughout the
hospital stay, and to risk factors encoded in a patient’s
medical history (Table 1). Candidate predictors were
chosen based on clinical experience, the frequency with
which variables are measured in the clinical context
where the model is likely to be applied, and existing lit-
erature [8].
Sample size
Each year, around 60,000 patients are seen in the ED at
QEHB. In 2014, more than 4500 patients were admitted
to QEHB and prescribed an antibiotic. Preliminary ana-
lysis suggests that 20% of these prescriptions were for
suspected UTI syndromes; hence, we expect ~ 5400 ad-
mitted patients using data from late 2011 to end of 2017
(6 years) [19]. Based on clinical experience, we expect a
similar number of patients with suspected UTI syn-
dromes to be discharged directly from the ED, resulting
in an estimated total training sample of ~ 10,800 pa-
tients. Assuming a prevalence of bacteriuria of 30% like
that reported by Taylor et al. previously, this would
imply > 30 events per variable when including all vari-
ables defined in Table 1.
Statistical analysis methods
Feature engineering and selection
All continuous predictors will be winsorized at the 1st
and 99th percentile to account for outliers and normal-
ised to lie within the range (0, 1). Categorical predictors
will be encoded in a full-rank encoding, combining levels
with a small number of cases (< 5%). Predictors with
zero variance will be excluded before analysis. For highly
correlated predictors (correlation coefficient > 0.9 using
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Table 1 Candidate predictors of bacteriuria measured (a) once at admission (constant throughout one hospital stay; time
independent) and (b) multiple times throughout a patient’s hospital stay (time-dependent)
Candidate predictor Definition Units/categories
(a) Measured at admission
Demographic
Age Recorded age at hospital admission in 10-year age bands (continuous age is unavail-
able due to privacy regulations)
18–24, 25–34,…, 95–104
Sex As recorded in the admission notes Male/female
Social deprivation Index of Multiple Deprivation (IMD) 2015 quintile Deciles (1–10)









Presence of a relevant ICD-10 code in the previous 5 years* Yes/no
Underlying urological
condition
Presence of a relevant ICD-10 code in the previous 5 years* Yes/no
Renal or urological
surgery
Presence of a relevant OPCS code in the previous 5 years* Yes/no
Immunosuppression Presence of a relevant ICD-10 code in the prior year* Yes/no




hospital in prior 7 days
Most recent discharge date from QEHB within 7 days of index attendance date Yes/no
Number of previous
admissions
Number of hospital spells at QEHB in the prior year Count (≥ 0)
Number of days spent
in hospital
Number of days spent as an inpatient at QEHB in the prior year Count (≥ 0)
Number of previous
ED attendances





Admission to QEHB with an ICD-10 code of UTI on discharge in the prior year* Yes/no
Previous ED
attendance for UTI





Number of hospital spells at QEHB with an ICD-10 code of UTI on discharge in the
prior 2 years*
Count (≥ 0)
Number of previous ED
attendances for UTI
Number of ED attendances at QEHB with ED diagnosis of lower UTI, pyelonephritis or
urosepsis in the prior year*
Count (≥ 0)
Previous urine culture Urine sample submitted at QEHB for microbiological diagnosis in prior year Yes/no
Previous bacteriuria Urinary pathogen identified at QEHB from blood or urine in prior year Yes/no
Previous resistant
pathogen
Drug-resistant pathogen identified at QEHB from blood or urine in prior year Yes/no
Prior antibiotic
consumption
Total antibiotic consumption in QEHB in prior year Defined daily doses (DDDs) (≥ 0)
[18]




Month of admission As recorded January,…, December
Day of year of
admission
As recorded Count (1–366)
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Table 1 Candidate predictors of bacteriuria measured (a) once at admission (constant throughout one hospital stay; time
independent) and (b) multiple times throughout a patient’s hospital stay (time-dependent) (Continued)
Candidate predictor Definition Units/categories
Day of week of
admission
As recorded Monday,…, Sunday
Investigations in the ED
Suspected diagnosis in
the ED
ED impression of clinical syndrome as recorded by the ED clinician Lower UTI, pyelonephritis,
urosepsis
Positive urinalysis Presence of leucocytes and/or nitrates in urinalysis Yes/no
Urinalysis
Leucocytes As recorded by the clinician (dipstick test) Positive/negative
Nitrates As recorded by the clinician (dipstick test) Positive/negative
White blood cells As recorded by the laboratory (flow cytometry) Count/μL
Red blood cells As recorded by the laboratory (flow cytometry) Count/μL
Epithelial cells As recorded by the laboratory (flow cytometry) Count/μL
Small round cells As recorded by the laboratory (flow cytometry) Count/μL
Bacteria As recorded by the laboratory (flow cytometry) Count/μL
Yeast As recorded by the laboratory (flow cytometry) Count/μL
Conductivity As recorded by the laboratory (flow cytometry) mS/cm
Casts As recorded by the laboratory (flow cytometry) Count/μL
Crystals As recorded by the laboratory (flow cytometry) Count/μL
(b) Measured multiple times throughout hospital stay†
Clinical observations
Heart rate As recorded Beats per minute
Respiratory rate As recorded Breaths per minute
Body temperature As recorded C°
Oxygen saturation As recorded Percent
Systolic blood pressure As recorded mmHg
AVPU As recorded Alert, verbal, pain, unresponsive
SEWS Standardised Early Warning Score as recorded or calculated based on heart rate,






C-reactive protein As recorded mg/L
Creatinine As recorded μmol/L
Acute kidney injury
score
Defined as the change in serum creatinine compared to an approximate baseline
measure (i.e. average creatinine in previous 6 months)
Stage 0 (1.0–1.5 × baseline),
stage 1 (1.5–1.9), stage 2 (2.0–
2.9) stage 3 (≥ 3.0)
Alkaline phosphatase As recorded IU/L
Bilirubin As recorded μmol/L
Platelets As recorded 109/L
Antibiotic treatment





Recorded administration of any of the following antibiotics: co-amoxiclav, piperacillin-






Recorded route of administration, giving precedence to intravenous (IV) antibiotics (i.e.
if multiple antibiotics are prescribed with ≥ 1 IV, treatment is classified as IV)
IV, oral, none
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Spearman’s rank correlation), one predictor will be re-
moved before analysis based on clinical judgement. Simi-
larly, predictors which are found to be largely missing
and might thus not be expected to be present when the
model will be used in practice at QEHB will be removed
from the analysis before fitting the models.
We will consider the use of fractional polynomials
(FP) with up to four degrees of freedom (i.e. 2 fractional
polynomial terms) for each numerical predictor [20, 21].
We will estimate the optimal number of FPs using the
Akaike Information Criterion. Once the best-fitting FPs
have been determined, we will consider models with all
predictors and parsimonious models selected via back-
wards feature elimination based on Wald statistics and
Rubin’s rules [22]. Since the large number of possible
predictors might limit the model’s usability in clinical
practice, we follow Taylor et al. and consider a minimal
model based on age, sex, urinalysis results and history of
UTI [8].
Type of model
Baseline model in the ED We will first develop a mul-
tivariable logistic regression model to predict bacterial
growth in the urine and/or blood sample at the end of
ED attendance. A prediction will be made for each pa-
tient based on the fitted value, which will serve as a
baseline comparison for all further models considered.
Landmarking models at distinct time points after
hospital admission Additional measurements taken
during the first couple of days in hospital may further
improve the predictive power of our risk prediction
models. We will develop a set of landmarking logistic re-
gression models [23] that predict the probability of bac-
terial growth in the ED urine sample at pre-defined
times t = {0, 12, 24, 36, 48, 60} hours after the patient
has left the ED and was admitted to the hospital ward.
In order to do so, we require a value for each included
predictor at time t. Since predictors are measured ir-
regularly throughout the patient’s hospital stay, we will
first train a multivariate generalized linear mixed model
(MGLMM) on all past predictor values up to time t to
estimate the most likely value of each predictor at time t
(see the “Missing data” section below for details). Values
at time t will be estimated using the best linear unbiased
predictors from the empirical Bayes posterior distribu-
tion of the random effects, conditional on past predictor
measurements [23]. The estimated predictor values will
then be fed to a logistic regression model that predicts
the probability of microbiological growth in the ED sam-
ple after having observed the patient for t hours. As a re-
sult, patients might have more than one prediction, one
for each time t at which they were still part of the at-risk
population. Only patients still admitted and without a
culture result at time t will be considered at-risk and will
be included in the fitting and evaluation of the logistic
regression model for time t.
Missing data
In EHR data, information is only recorded when events
take place and we cannot distinguish between cases in
which a test or diagnosis was not made and cases in
which they were made but not recorded. Consequently,
if historical variables such as co-morbidities, procedures,
admission records, test results and procedures are not
recorded (e.g. because they were performed at another
hospital), we will have to assume that these events did
not take place. For other variables with missing values
that should have been obtained during the current visit
(particularly vital signs and laboratory measurements),
we will examine the pattern of missingness and impute
values where appropriate depending on the type of pre-
diction model.
Our baseline model is a logistic regression, which re-
quires a non-missing value for each included predictor.
We will use multivariate imputation by chained equa-
tions (MICE) based on the assumption that data are
missing at random, i.e. whether a variable is missing or
not only depends on the values of observed variables
[24]. Following standard MICE procedures [25], we will
include all predictors as well as the prediction outcome
in the imputation procedure and impute 5 datasets with
10 iterations per dataset (Table 2). Depending on com-
putational feasibility, we will aim to impute up to 100
datasets for our final model to ensure that we obtain ro-
bust imputations. Model training will be performed on
the imputed development dataset. However, we cannot
use the same imputation procedure to evaluate our
models since we expect predictors to also be missing
during model deployment. When used in practice, our
model must impute any missing data in real-time before
Table 1 Candidate predictors of bacteriuria measured (a) once at admission (constant throughout one hospital stay; time
independent) and (b) multiple times throughout a patient’s hospital stay (time-dependent) (Continued)
Candidate predictor Definition Units/categories
Dosage As recorded DDDs (≥ 0) [18]
*Detailed code lists available in the appendix
†For each time-dependent variable, we will also consider the change in value compared to the last observed measurement
‡Excluding anti-tuberculosis and anti-leprosy medication
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making a prediction, but at this point, no outcome will
be available yet to use in the imputation. This will tend
to result in suboptimal imputations when the model is
used in practice [25]. To obtain an honest estimate of
the performance of our models, we will evaluate them
on a second set of imputations that were fit without
using the outcome in the imputation procedure, emulat-
ing the situation in which the model will ultimately be
used [26].
For our time-dependent models, the nature of missing
data slightly differs. Values for each predictor might have
been recorded never, once or multiple times before time
t and we are interested in estimating the most likely
value at time t. To estimate a good approximation for
each predictor, we will separately fit a MGLMM at each
landmarking time [23]. Each model will include fixed in-
tercepts and slopes for each predictor and a time-
dependent covariate indicating concurrent antibiotic
treatment. We will consider correlation structures of
varying complexity, with uncorrelated and correlated
patient-specific random intercepts and/or slopes for each
predictor. If the MGLMM is intractable, we will consider
a simpler last observation carried forward (LOCF)
method to estimate predictor values at time t, or a mix-
ture of LOCF and MGLMM.
Model validation
Clinical diagnosis of bacterial UTI requires the presence
of urinary symptoms in addition to microbiological cul-
ture. Bacteriuria in the absence of urinary symptoms
(called asymptomatic bacteriuria) should not be treated
with antibiotics [2]. Prevalence of asymptomatic bacteri-
uria differs between patient groups and increases for ex-
ample with age. Whereas a urine sample might be sent
for culture in many different patients “just in case”, a
clinically usable model to confirm or rule out suspected
bacterial UTI needs to perform especially well in pa-
tients with urinary symptoms. In our main analysis, we
will therefore validate our models in the subgroup of pa-
tients with a suspected ED diagnosis of lower UTI or py-
elonephritis, and our final model will be chosen based
on the performance in this group. This group differs
from the training population, which will include all pa-
tients irrespective of ED diagnosis to increase sample
size and provide our model with enough power to learn
general relationships. In a secondary analysis, we will
also evaluate the performance of our models in patients
without an ED diagnosis of UTI as well as in different
age groups, by sex and by outcome (i.e. discharge diag-
nosis, death, admission to intensive care unit, length of
stay). We will further consider training our model using
only data from patients with a suspected ED diagnosis of
lower UTI or pyelonephritis for training to ensure that a
heterogeneous training population is not obscuring im-
portant relationships in patients with suspected UTI. Fi-
nally, we will perform secondary analyses limited to the
first visit of each patient and to data after 2015, assessing
the impact of repeated patient visits and the impact of
increased culture thresholds on our models.
Internal validation Model discrimination in each sce-
nario will be assessed via multiple performance metrics:
AUROC, Brier score, area under the precision-recall
curve (AUPRC), specificity and negative predictive value
(NPV). We will estimate each model’s specificity and
NPV at a pre-set sensitivity of 95%, which will evaluate
the model’s ability to be used as a screening tool to rule
out bacterial UTI. We will assess how well predicted and
observed probabilities correspond within each predicted
decile (model calibration) by creating a calibration plot
and estimating the calibration slope. An estimated slope
> 1 indicates underfitting, whereas a slope < 1 indicates
overfitting.
Evaluating the model only on the development dataset
or a single validation dataset leads to optimistic estima-
tions of the true model performance (henceforth called
the apparent performance) [27]. To obtain a more reli-
able estimate of model performance, we will draw at
least 100 bootstrap samples of the development dataset.
Where computation time allows for it, we will consider
up to 1000 bootstrap samples. All preprocessing and
analysis steps including missing data imputation, estima-
tion of fractional polynomials, feature selection and
model evaluation will be carried out independently
within each bootstrapped sample to avoid any data leak-
age [28]. The result will be one final model per boot-
strapped sample. Evaluating each model on the
bootstrap sample in which it was developed provides an-
other estimate of the apparent performance, this time
within the bootstrap. To estimate the magnitude of opti-
mism in this bootstrapped apparent performance, we
will simultaneously evaluate the bootstrapped model in
the original development dataset (called test perform-
ance). The difference between test performance and
bootstrapped apparent performance will be an estimate
of model optimism.
Averaging estimates of the optimism across all boot-
strapped samples results in a stable estimate of the opti-
mism [27]. The final, optimism-corrected (“true”)
Table 2 Conditional models used in the multivariate imputation
by chained equations
Variable type Conditional model
Continuous Predictive mean matching with type 1
matching and 10 donors
Binary Logistic regression
Multinomial Polytomous regression
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estimate of model performance will then be calculated
as follows:
performance ¼ apparentoriginal −mean optimismð Þ
¼ apparentoriginal − 1B
XB
b¼1 apparentb − testoriginal
 
All metrics used in the model evaluation (AUROC,
AUPRC, specificity and NPV) will be adjusted for
optimism.
External validation The performance of the model
(AUROC, AUPRC, specificity and NPV) in a new dataset
will be evaluated using EHRs from patients with suspected
UTI who were admitted to QEHB between 1 January 2018
and 31 March 2019. We will summarise average perform-
ance and calibration in this temporally independent sam-
ple. We will further validate the model in a geographically
independent sample of patients from University College
London Hospitals NHS Foundation Trust.
All analyses will be performed using the statistical soft-
ware R [29] including but not necessarily limited to the
packages: tidyverse [30], tidymodels [31], mice [32] and
mfp [33].
Discussion
The need to reduce inappropriate antibiotic prescribing in
secondary care is widely acknowledged, but progress is
thwarted by the lack of rapid and reliable diagnostic tests
for bacterial infection. Risk prediction models using data
contained within EHR offer a new approach to improve
antibiotic prescribing decisions, by integrating clinical and
demographic data with test results to stratify patients ac-
cording to their likelihood of bacterial infection.
However, diagnostic uncertainty represents a major
obstacle in the application of risk prediction models for
bacterial infection. Clinical infection syndromes often
overlap, and diagnoses are often not confirmed by mi-
crobial culture. This makes it difficult to reliably distin-
guish infection from non-infectious conditions, but also
to discriminate between clinical infection syndromes.
For these reasons, we have not attempted to develop a
model which supports decision around antibiotic initi-
ation in the ED, recognising that few doctors will be
willing to withhold antibiotics if patients are unwell and
the diagnosis is uncertain. Instead, we have opted for a
model that identifies patients who may benefit from
early antibiotic cessation since they are actually at low
risk of bacterial UTI. Descriptive analyses of patients
who have been categorised by the model as low/high risk
of bacterial UTI will identify categories of patients who
are most likely to be low risk, for example based on age,
sex and UTI syndrome at presentation. This will be used
in conjunction with expert clinical opinion to define a
“low-risk” population of patients who have been treated
with antibiotics for suspected UTI but are unlikely to
benefit from antibiotic treatment. Individuals from this
population sub-group will be asked to participate in a
proof of concept trial, and randomised to either stop an-
tibiotics early, or to continue antibiotic as per standard
care. The trial will assess the safety and feasibility of
early antibiotic cessation in these patients and lay the
foundation for a future multi-centre trial. It will also
demonstrate the potential use of EHR datasets to guide
prescribing decisions.
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